ÇзÂ
ÀÌÈ¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ Á¹¾÷ ¾ÆÁÖ´ëÇб³ ÀϹݴëÇпø ÀÇÇаú ¼®»ç ¾ÆÁÖ´ëÇб³ ÀϹݴëÇпø ÀÇÇаú ¹Ú»ç |
°æ·Â
¹Ì±¹ ¿¹ÀÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ³»°ú / Ææ½Çº£´Ï¾ÆÁÖ¸³´ëÇб³ ¿¬¼ö ÇѸ²´ëÇб³°³²¼º½Éº´¿ø ³»°ú Àü°øÀÇ ¼ö·á ºÎõ¼¼Á¾º´¿ø ³»°ú °úÀå ¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ ÀüÀÓÀÇ/ Áß¹®ÀÇ´ë ÀüÀÓ°»ç ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ Á¶±³¼ö/ ºÎ±³¼ö/ úÞ ±³¼ö Marquis Who's Who : ¼¼°è Àθí»çÀü µîÀç îñ ³»ºÐºñ´ç´¢°©»ó¼±¼¾ÅÍÀå îñ ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ³»ºÐºñ³»°ú ºÐ°úÀå îñ ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ³»°ú °úÀå / ¾à»çÀ§¿øÀå QI À§¿øÀå 2015 ÃÖ°í º¸°ÇÀÇ·áÀÎ 100ÀÎ ¼±Á¤ - Top 100 Health Professional Biographical Center, IBC) |
ÇÐȸȰµ¿
2002 ~ 2004´ëÇÑ´ç´¢º´ÇÐȸ ¿ªÇÐÀ§¿øȸ À§¿ø 2002 ~ 2003´ëÇÑ´ç´¢º´ÇÐȸ ³ëÀδ索º´ ¼Ò¿¬±¸È¸ °£»ç 2007 ~ ´ëÇÑ´ç´¢º´ÇÐȸÁö ³í¹®½É»ç À§¿ø 2007 ~ 2012³»ºÐºñÇÐȸ ½Å°æ³»ºÐºñ ÇмúÀ§¿øȸ À§¿ø 2007 ~ 2008´ëÇѳ»ºÐºñÇÐȸ °¡À̵å¶óÀΠåÁ¤ TFT ´ëÇÑ´ç´¢º´ÇÐȸ ÇмúÀ§¿øȸ À§¿ø(2018~2019, 2012~2013) 2008 ~ 2009´ëÇÑ´ç´¢º´ÇÐȸ °£ÇàÀ§¿øȸ À§¿ø 2008 ~ 2013´ëÇÑ´ç´¢º´ÇÐȸ È«º¸À§¿øȸ À§¿ø 2009 ~ ´ëÇѳ»ºÐºñÇÐȸÁö ³í¹®½É»ç À§¿ø 2009 ~ 2010Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ´ë¿ÜÇù·ÂÀ§¿øȸ °£»ç 2009 ~ 2010Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ÇмúÀ§¿øȸ À§¿ø 2010 ~ 2018´ëÇÑ´ç´¢º´ÇÐȸ Áø·áÁöħÀ§¿øȸ À§¿ø 2010 ~ 2011´ëÇÑ´ç´¢º´ÇÐȸ ¿¬±¸À§¿øȸ À§¿ø 2011 ~ 2012´ëÇѳ»ºÐºñÇÐȸ ÀÓ»ó½ÃÇèÀ§¿øȸ ÀÌ»ç 2011 ~ 2012Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ±¹Á¦À§¿øȸ À§¿ø 2011 ~ 2014Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ±³À°À§¿øȸ À§¿ø 2013 ~ 2014´ëÇѳ»ºÐºñÇÐȸ ÇмúÀ§¿øȸ À§¿ø 2014 ~ 2015´ëÇÑ´ç´¢º´ÇÐȸ À繫ÀÌ»ç 2014 ~ 2016Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ´ë¿ÜÇù·ÂÀ§¿øȸ À§¿ø 2017 ~ 2018Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ±âȹÀ§¿øȸ À§¿ø 2013 ~ Áúº´°ü¸®º»ºÎ ±¹°¡°Ç°°ËÁø ÀÌ»óÁöÁúÇ÷Áõ ºÐ¾ß ÀÚ¹®À§¿ø 2008 ~ ÇѸ²ÀÇ´ë Áß¾Ó¾à»ç½ÉÀÇÀ§¿øȸ À§¿ø(³»ºÐºñºÐ°ú) 2016 ~ ½Ä¾àó Áß¾Ó¾à»ç½ÉÀÇÀ§¿øȸ À§¿ø 2017 ~ 2019´ëÇѳ»ºÐºñÇÐȸ °í½ÃÀÌ»ç 2016 ~ 2019´ëÇѳ»°úÇÐȸ ºÐ°úÀü¹®ÀÇ °ü¸®À§¿ø(³»ºÐºñºÐ°ú À§¿øÀå) 2018 ~ Çѱ¹°úÇбâ¼ú´ÜüÃÑ¿¬ÇÕȸ ÀÚ¹®À§¿ø 2018 ~ ÇѸ²´ëÇб³µ¿Åº¼º½Éº´¿ø ¾à»çÀ§¿øÀå 2019 ~ Çѱ¹º¸°ÇÀǷῬ±¸¿ø ÀÚ¹®À§¿ø 2019 ~ ´ëÇѳ»°úÇÐȸ ÆòÀÇ¿ø 2019 ~ ´ëÇѳ»°úÇÐȸ À±¸®ÀÌ»ç 2021 ~ ´ëÇÑ´ç´¢º´ÇÐȸ °æÀÎÁöȸ ºÎȸÀå 2021 ~ ´ëÇѳ»ºÐºñÇÐȸ ±³°ú¼°³Á¤ÀÌ»ç ´ëÇÑ´ç´¢º´ÇÐȸ/´ëÇѳ»ºÐºñÇÐȸ/Çѱ¹ÁöÁúµ¿¸Æ°æÈÇÐȸ ÆòÀÇ¿ø 2022 ~ ´ëÇÑ´ç´¢º´ÇÐȸ ºÎȸÀå ´ëÇѳ»°úÇÐȸ ºÎȸÀå 2025 ~ ´ëÇѳ»ºÐºñÇÐȸ ÀÌ»çÀå |
¼ö»óÀÌ·Â
ÇѸ²ÀÇ´ë °³²¼º½Éº´¿ø ³í¹® ´ÙÀÛ»ó ´ëÇѳ»ºÐºñÇÐȸ Best Submission Awards |
³í¹®/Àú¼
ÇмúÆíÁý È°µ¿ 1. äºÀ³², À̼º±Ô, È«Àº°æ, ±èÀ±Á¤, ¿ÀÇý¸², Á¤À±¼®, ÀÌ°ü¿ì, ±èÇö¸¸. Çѱ¹ÀÎ Á¦2Çü ´ç´¢º´ º´Àο¡¼ Àν¶¸° ºÐºñ´É°ú ÀúÇ×¼ºÀÇ ¿ªÇÒ. ´ëÇÑ´ç´¢º´ÇÐȸ. 22(4):491-503, 1998 2. Hong EG, Suh Y, Chung YS, Kim HM, Shin GT, Chung DY, Park RW. A Case of Nephrogenic Diabetes Insipidus Caused by Obstructive Uropathy due to Prostate Cancer. YMI. 41(1):150-4, 2000 3. À̼º±Ô, äºÀ³², È«Àº°æ, ³ëÇý¸², Á¶Çö°æ, ±èÀ±Á¤, À̴̹ö, Á¤À±¼®, ÀÌ°ü¿ì, Á¶³²ÇÑ, ±èÇö¸¸. Á¦2 Çü ´ç´¢º´ ¿Ü·¡ ȯÀÚÀÇ ºñ¸¸µµ¿¡ µû¸¥ ¹Ì¼¼Ç÷°ü ÇÕº´Áõ. ´ç´¢º´ÇмúÁö. 24(1):60-7, 2000 4. Á¶³²ÇÑ, È«Àº°æ. °æ±¸´çºÎÇÏ °ËÁø½Ã »ç¿ëµÇ´Â Áø´Ü¿ë¾×ÀÇ ³óµµ Â÷ÀÌ¿¡ µû¸¥ Ç÷´çº¯È ¹× ¼±È£µµ ºñ±³: 75±×·¥ °æ±¸´çºÎÇϽà 25% ¿ë¾×(296mL)°ú 50% ¿ë¾×(150mL)ÀÇ ºñ±³ µ¿¹° ¹× ÀÓ»ó ½ÃÇ迬±¸. ´ëÇÑ´ç´¢º´ÇÐȸ. 24(3):385-93, 2000 5. ±èÀ¯¸®, Á¶¿ë¿í, ¹Ú¼®¿ø, È«Àº°æ, Á¶À±°æ, ÀÌÈ¿µ, ÀüÇý¼±, ¼ÛÀ¯ºÀ, ¾È¸í¿Á, ±è¼¼Çö, ÀÌ»óÁ¾. Àӽżº ´ç´¢º´ÀÇ Àç¹ß·ü¿¡ °üÇÑ ¿¬±¸. ÀÓ»ó´ç´¢º´ÇмúÁö. 2(1) : 74-82, 2001 6. Hong EG, Noh HL, Lee SK, Chung YS, Lee KW, Kim HM. Insulin and glucagon secretion, and morphological change of pancreatic islets in OLETF rats, a model of type 2 diabetes mellitus. JKMS. 17(1) : 34-40, 2002 7. Â÷¿µ¼ö, ÃÖÈ«¿±, ¹ÚÁø°æ, ÀÌÁØ, ÀÓ»ó¿í, Â÷µ¿ÈÆ, È«Àº°æ, ¹Ú¼®¿ø, Á¶À¯¸®, Á¶¿ë¿í, ÀÌ»óÁ¾. »õ·Ó°Ô Áø´ÜµÈ Á¦ 2Çü ´ç´¢º´ ȯÀÚ¿¡¼ÀÇ ÁÂ½É½Ç À̿ϱ⠱â´ÉÀå¾Ö. ´ëÇѳ»°úÇÐȸÁö. 62(4) :422-9, 2002 8. äºÀ³², È«Àº°æ, À̼º±Ô, Á¤À±¼®, ÀÌ°ü¿ì, ±èÇö¸¸. ÀÏÂ÷¼º °ñ´Ù°øÁõ ¿©¼º ȯÀÚ¿¡¼ ÁÖ±âÀûÀÎ pamidronate Á¤ÁÖÄ¡·á. ´ëÇѳ»ºÐºñÇÐȸÁö. 16(2) :221-30, 2001 9. ±èÈ¿Á¤, ¹ÚÁö¿ø, À̼öÁø, ÇÏ⿵, Á¤À±¼®, ÀÌ°ü¿ì, ±èÇö¸¸, ±èÇö¼ö, ±èȿö, Á¶ÀçÇö, È«Àº°æ. Pamidronate Á¤¸ÆÅõ¿©°¡ ¾Ç¼ºÁ¾¾ç(À¯¹æ¾Ï ¶Ç´Â ´Ù¹ß¼º°ñ¼öÁ¾)¿¡ ÀÇÇÑ °ñÁúȯ¿¡ ¹ÌÄ¡´Â ¿µÇâ - °ñÅëÁõ, °ñ´ë»çÁöÇ¥ ¹× °ñ¹Ðµµ¿¡ °üÇÑ ¿¬±¸. ´ëÇÑ°ñ´ë»çÇÐȸÁö. 8(2) :147-57, 2001 10. ³ë½ÂÇõ, ÃÖÁö¿ë, ³²Åø¸, ±èÇö±Ô, À̼ºÁø, Á¤Àΰæ, È«Àº°æ, ÃÖö¼ö, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. °áÇÙ¼º ³ú¼ö¸·¿°¿¡ µ¿¹ÝµÈ ³ú¼º ¿°ºÐ¼Ò½ÇÁõÈıº. ´ëÇѳ»ºÐºñÇÐȸÁö. 17(5) :698-704, 2002 11. À̼ºÁø, ÀÌÇ⸲, Á¤Àΰæ, È«Àº°æ, ÃÖö¼ö, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ÀӽŰú µ¿¹ÝµÈ ¸²ÇÁ±¸¼º ³úÇϼöü¿° 1¿¹. ´ëÇѳ»ºÐºñÇÐȸÁö. 17(5) :705-12, 2002 12. ÀÌ»ó¹«, È«Àº°æ, À̼ºÁø, Á¤Àΰæ, ±èÇö±Ô, ÃÖö¼ö, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ¿ø¹ß¼º ºÎ°©»ó¼±±â´ÉÀúÇÏÁõÀÇ ÀÓ»óÀû °íÂû. ´ëÇѳ»°úÇÐȸÁö. 64(1) :70-8, 2003 13. À̼ºÁø, ¹Úö¿µ, Á¤Àΰæ, È«Àº°æ, ÃÖö¼ö, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì, P.Reed Larsen. Á¦1Çü Å»¿ä¿ÀµåÈ¿¼Ò À¯ÀüÀÚ °©»ó¼±È£¸£¸ó ¹ÝÀÀÈ¿¼Ò¿¡¼ T3 Àڱؿ¡ µû¸¥ °©»ó¼±È£¸£¸ó ¼ö¿ëü ¿ªµ¿ÇÐ ¸ðµ¨. ´ëÇѳ»ºÐºñÇÐȸÁö. 18(3) :283-95, 2003 14. ³²Åø¸, Á¶ÇѼö, ÀÌÁø¼, ¼Û¿µ¸², ±èµÎ¸¸, µÎ¿µÃ¶, ¹Úö¿µ, Á¤Àΰæ, È«Àº°æ, À̼ºÁø, ¿À±â¿ø, ±èÇö±Ô, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ±×·¹À̺꽺º´¿¡¼ Ä¡·á¿¡ µû¸¥ Æ󵿸ƾÐÀÇ º¯È. ´ëÇѳ»ºÐºñÇÐȸÁö. 18(5) :465-72, 2003 15. À̼ºÁø, ÀÌÈ£±Ç, ¹Úö¿µ, Á¤Àΰæ, È«Àº°æ, ¿À±â¿ø, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ºÎ½ÅÇÇÁú È£»ê¼º °ú¸³¼¼Æ÷Á¾ 1¿¹. ´ëÇѳ»ºÐºñÇÐȸÁö. 19(1) :82-9, 2004 16. ±èÈñ¼±, À±È£¼º, °íâ¿Á, ±èÇö±Ô, ¹Úö¿µ, À̼ºÁø, ¿À±â¿ø, Á¤Àΰæ, È«Àº°æ, ÃÖö¼ö, ±èµÎ¸¸, ÀÓ¼ºÈñ, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì, ¿Àµ¿Áø. À¯»êÁõ¿¡ ÀÇÇØ ÀºÆóµÈ ½ÉÇÑ ÀúÇ÷´ç 1¿¹(Áõ·Ê). ´ëÇѳ»ºÐºñÇÐȸÁö. 19(4) :406-10, 2004 17. ¼Õ±¤Ç¥, 俵Á¦, ÀÌÅÂÀ¯, Á¤Àΰæ, Çã¹Ì³ª, Á¶±¸¿µ, ÀÌ¿µ, À̼ºÁø, ¹Úö¿µ, ¿À±â¿ø, È«Àº°æ, ±èÇö±Ô, À¯Àç¸í, ±èµÎ¸¸, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. Á¦2Çü ´ç´¢º´¿¡¼ ´ë»çÁõÈıºÀÇ µ¿¹ÝÀÌ °æµ¿¸Æ ³»Á߸· µÎ²²¿Í ½ÉÇ÷°ü ÁúȯÀÇ À§Çè ÀÎÀÚ¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ç´¢º´ÇмúÁö. 28(5) :392-406, 2004 18. ±èÁ¾Çù, ½ÅÇö¿ø, Á¤Àΰæ, Á¶¼ºÈÖ, ¹Î¼±Á¤, À̼ºÁø, ¹Úö¿µ, ¿À±â¿ø, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ºñ¸¸µµ¿¡ µû¸¥ Adiponectin, Leptin, Ghrelin°ú Àν¶¸° ÀúÇ×¼º, ½ÉÇ÷°ü À§ÇèÀÎÀÚÀÇ »óÈ£ ¿¬°ü¼º. ´ëÇѳ»°úÇÐȸÁö. 69(6) :631-41, 2005 19. ¹Ú±¤Çõ, À±¼ºº¸, Á¶¹ÎÈ£, È«Àº°æ, À̼ºÁø, Á¤Àΰæ, ¹Úö¿µ, ¿À±â¿ø, ±èÇö±Ô, À¯Àç¸í, ±èµÎ¸¸, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì, ¿ÀÈ￵, ±èÁø¹è, ¹éÀÏÇö, ÀÌ¸í¼®. ´ç´¢º´È¯ÀÚ¿¡¼ ¹ß»ýÇÑ À§½Äµµ ¿ª·ù ÁúȯÀÇ ÀÓ»óÀû Ư¼º ¹× À§Çè¿ä¼Ò. ´ëÇÑ´ç´¢º´ÇÐȸ. 29(4) :358-66, 2005 20. À¯ÁöÇö, ¹®È«ÁÖ, ¹Úö¿µ, À̼ºÁø, Á¤Àΰæ, È«Àº°æ, ¿À±â¿ø, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì, ¹Î¼ö±â. ÇϽøðÅä °©»ó¼±¿° ȯÀÚ¿¡¼ Æ÷»ó±âÅ¿¡ ÀÇÇØ ¹ß»ýµÈ T3-°©»ó¼±Áßµ¶Áõ 1¿¹(Áõ·Ê). ´ëÇѳ»ºÐºñÇÐȸÁö. 20(3) :294-8, 2005 21. ±èÇö±Ô, Á¶¹ÎÈ£, ¹Úö¿µ, À̼ºÁø, ¿À±â¿ø, Á¤Àΰæ, È«Àº°æ, ÀÓ¼ºÈñ, ±èµÎ¸¸, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì, ±èÁøȯ, ³ë¿µ¼ö. °©»ó¼± ºÐȾÏÀÇ ¼ö¼úÈÄ ¹æ»ç¼º¿ä¿Àµå Åõ¿©¸¦ À§ÇÑ Àüóġ ±â°£. ´ëÇѳ»ºÐºñÇÐȸÁö. 20(5) :460-6, 2005 22. Park SY, Cho YR, Finck BN, Kim HJ, Higashimori T, Hong EG, Lee MK, Danton C, Deshmukh S, Cline GW, Kalinowski A, Russell KS, Kim YB, Kelly DP, Kim JK. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-a causes insulin resistance in heart and liver. Diabetes. 54(9) :2514-24, 2005 23. ±ÇÇõ»ó, ±è±¤¿ø, ±è´ëÁß, ±è¼º·¡, ¹Î°æ¿Ï, ¹Ú°¼, ¹Ú¼®¿ø, ¹Ú¿ë¼ö, ¹ÚÀ̺´, ¹ÚÁ¤Çö, ¹ÚÁß¿, ¹Úż±, ¹é¼¼Çö, ¼º¿¬¾Æ, ¼ÕÇö½Ä, ¾Èö¿ì, À±°ÇÈ£, À±¼®±â, À̼®ÀÎ, ÀåÇÐö, Á¤ÃáÈñ, Á¶³²ÇÑ, Á¶Á¤±¸, Ãְ湬, ÇϽ¿ì, È«Àº°æ. 2003³âµµ °æ±âµµÁö¿ª ´ç´¢º´ ¿ªÇÐÁ¶»ç °á°ú. ´ëÇÑ´ç´¢º´ÇÐȸ. 29(2):97-102,2005 24. Park SY, Cho YR, Kim H J, Hong EG, Higashimori T, Lee SJ, Goldberg IJ, Shulman GI, Najjar SM, Kim JK. Mechanism of glucose intolerance in mice with dominant-negative mutation of CEACAM1. Am J Physiol Endocrinol Metab. 291(3) :E517-24, 2006 25. Matsui T, Nagoshi T, Hong EG, Luptak I, Hartil K, Li L, Gorovits N, Charron MJ, Kim JK, Tian R, Rosenzweig A. Effects of chronic Akt activation on glucose uptake in the heart. Am J Physiol Endocrinol Metab. 290(5) :E789-97, 2006 26. Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK, Bennett AM. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab. 4(1) :61-73, 2006 27. ¹®È«ÁÖ, °Áر¸, Á¶¹ÎÈ£, À̺´¿Ï, ¹Úö¿µ, À̼ºÁø, È«Àº°æ, À¯Àç¸í, ±èµÎ¸¸, ÀÓ¼ºÈñ, ±èÇö±Ô, ÀÓÁ¾À±, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ´ç´¢º´ÀÇ µ¿¹ÝÀ¯¹«°¡ ±Þ¼º °ü»óµ¿¸Æ ÁõÈıºÀÇ À§ÇèÀÎÀÚ¿¡ ¹ÌÄ¡´Â ¿µÇâ. ´ëÇÑ´ç´¢º´ÇÐȸ. 30(6) :435-41, 2006 28. Á¶¹ÎÈ£, À¯Àç¸í, ¹®È«ÁÖ, °Áر¸, À̺´¿Ï, À̼ºÁø, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. Á¦2Çü ´ç´¢º´È¯ÀÚ¿¡¼ pioglitazone 15mg Ä¡·áÀÇ °æµ¿¸Æ ³»Á߸· µÎ²²¿¡ ´ëÇÑ È¿°ú. ÀÓ»ó´ç´¢º´ÇмúÁö. 7(4) :358-67, 2006 29. Á¶¹ÎÈ£, À¯Àç¸í, ¹®È«ÁÖ, °Áر¸, À̺´¿Ï, À̼ºÁø, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. ´ç´¢º´È¯ÀÚ¿¡¼ IntimascopeÀ» ÀÌ¿ëÇÑ °æµ¿¸Æ ³»Á߸· µÎ²² ÃøÁ¤ÀÇ Á¤È®¼º°ú È¿À²¼º. ÀÓ»ó´ç´¢º´ÇмúÁö. 7(4) :349-57, 2006 30. Gray S, Wang B, Orihuela Y, Hong EG, Fisch S, Haldar S, Cline GW, Kim JK, Peroni OD, Kahn BB, Jain MK. Regulation of Gluconeogenesis by Kruppel-like Factor 15. Cell Metab. 5(4) :305-12, 2007 31. È«Àº°æ. ³ëÀÎ ´ç´¢º´ ȯÀÚÀÇ ¾à¹°Ä¡·á. ÀÓ»ó´ç´¢º´ÇмúÁö. 8(1) :28-33, 2007 32. ±è¹ÌÁ¤, À̺´¿Ï, Á¤Àΰæ, °Áر¸, À̼ºÁø, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. »õ·Î¿î µ¹¿¬º¯À̸¦ °¡Áø °¡Á·¼º ÁßÃß¼º ¿äºØÁõ(Áõ·Ê). ´ëÇѳ»ºÐºñÇÐȸÁö. 22(2) :118-24, 2007 33. Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, Higashimori T, Zhang Z, Jung DY, Ola MS, Lanoue KF, Leiter EH, Kim JK. Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab. 293(1) :E327-36, 2007 34. ½ÅÇö¿ø, Á¤Àΰæ, Á¶±¸¿µ, ÃÖö¿µ, ±èÁ¾¿±, 俵Á¦, Á¶¹ÎÈ£, À̺´¿Ï, À̼ºÁø, ¹Úö¿µ, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, ¹Ú¼º¿ì. ¼ºÀåÈ£¸£¸óÀÌ °áÇÌµÈ ³úÇϼöü±â´ÉÀúÇÏÁõ ȯÀÚ¿¡¼ ¼ºÀåÈ£¸£¸ó Ä¡·áÈÄ Á×»ó°æÈÁõ ÁöÇ¥ ¹× ¾ÆµðÆ÷»çÀÌÅäÄ«ÀÎÀÇ º¯È. ´ëÇѳ»ºÐºñÇÐȸÁö. 21(6):515-25, 2007 35. Delibegovic M, Bence KK, Mody N, Hong EG, Ko HJ, Kim JK, Kahn BB, Neel BG. Improved Glucose Homeostasis in Mice with Muscle-Specific Deletion of Protein-Tyrosine Phosphatase 1B. Mol Cell Biol. 27(21):7727-34, 2007 36. Hong EG, Jung DY, Ko HJ, Zhang Z, Ma Z, Jun JY, Kim JH, Sumne AD, Vary TC, Gardner TW, Bronson S, Kim JK. Nonobese, Insulin-Deficient Ins2Akita Mice Develop Type 2 Diabetes Phenotypes Including Insulin Resistance and Cardiac Remodeling. Am J Physiol Endocrinol Metab. 293(6):E1687-96, 2007 37. Atsumi T, Cho YR, Leng L, McDonald C, Yu T, Danton C, Hong EG, Mitchell RA, Metz C, Niwa H, Takeuchi J, Onodera S, Umino T, Yoshioka N, Koike T, Kim JK, Bucala R. The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol. 2007 Oct 15;179(8):5399-406. 38. Á¶¹ÎÈ£, È«¼ºÈ£, ¹ÚÁ¾±Ô, È«Àº°æ, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ. °©»ó¼±±â´ÉÇ×ÁøÁõ ȯÀÚ¿¡¼ ¹ß»ýÇÑ Ç×°©»ó¼±Á¦ °üÀý¿° ÁõÈıº 1¿¹(Áõ·Ê). ´ëÇѳ»°úÇÐȸÁö. 73(S3):S985-8, 2007 39. ÀÌÇظ®, È«Àº°æ, À¯Àç¸í. Á¦2Çü ´ç´¢º´ÀÇ »õ·Î¿î ¾ÆÇü: Ketosis-prone Á¦2Çü ´ç´¢º´ÀÇ °íÂû. ÀÓ»ó´ç´¢º´ÇмúÁö. 8(3):173-9, 2007 40. ÇÑÀçÇÊ, À̼ºÁø, ÃÖ°æÂù, ¹Ú¿µÀÇ, ÀÌÇظ®, °Áر¸, ·ù¿ÁÇö, ±èö½Ä, À̺´¿Ï, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, À¯ÇüÁØ, ÃÖ¹®±â. °©»ó¼± À¯µÎ¾Ï ¿ø¹ß Á¶Á÷°ú Àç¹ßµÈ ¸²ÇÁÀý ÀüÀÌ Á¶Á÷¿¡¼ Retinioc Acid Receptor B ´Ü¹é ¹ßÇöÀÇ ÀÓ»óÀû ÀÇÀÇ. ´ëÇѳ»ºÐºñÇÐȸÁö. 22(6):419-427, 2007 41. Lee S, Muniyappa R, Yan X, Chen H, Yue LQ, Hong EG, Kim JK, Quon MJ. Comparison Between Surrogate Indexes of Insulin Sensitivity/Resistance and Hyperinsulinemic-Euglycemic Clamp Estimates in Mice. Am J Physiol Endocrinol Metab. 294(2):E261-270, 2008 42. È«Àº°æ. ´ç´¢º´°ú ½ÉÇ÷°üÁúȯ -½ÉÇ÷°üÁúȯÀÇ ¿¹¹æ ¹× Ä¡·á¿¡ ´ëÇÑ ¹Ì±¹´ç´¢º´ÇÐȸ ±Ç°í¾È, 2008. ÀÓ»ó´ç´¢º´ÇÐȸÁö. 294(2):E261-270, 2008 43. È«Àº°æ. ´ç´¢º´¼º ½ÅÁõ - Lithospermic acid B(LAB)ÀÇ ¿¹¹æÈ¿°ú. ´ç´¢º´ÇÐȸÁö. 32(1):7-9, 2008 44. ½Å¿µÃ¶, À¯Àç¸í, ÀÌÇظ®, ¿ì°æÈñ, ·ù¿ÁÇö, °Áر¸, ±èö½Ä, À̺´¿Ï, À̼ºÁø, ±èÇö±Ô, È«Àº°æ, ±èµÎ¸¸, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. ¾ÆÅäÇǼº ÇǺο° ȯÀÚ¿¡¼ ½ºÅ×·ÎÀ̵å Ä¡·áÈÄ ¹ß»ýÇÑ ´ç´¢º´¼º ÄÉÅæ»êÁõ 1¿¹. ÀÓ»ó´ç´¢º´. 9(1):140-144, 2008 45. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmann A, Kulkarni RN, Kim JK, Najjar SM. Carcinoembryonic Antigen-Related Cell Adhesion, A Link Between Insulin and Lipid Metabolism. Diabetes. 57(9):2296-2303, 2008 46. HJ Yoo, HG An, SY Park, OH Ryu, HY Kim, JA Seo, EG Hong, DH Shin, YH Kim, SG Kim, KM Choi, IB Park, JM Yu, SH Baik. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes research and clinical practice. 82(1):73-79, 2008 47. À̼Èñ, ±è¼º¿, ÀÌÇظ®, °Áر¸, ·ù¿ÁÇö, ±èö½Ä, À̺´¿Ï, À̼ºÁø, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. Ⱦ¹®±Ù À¶ÇØÁõ°ú µ¿¹ÝµÈ °©»ó¼± Áßµ¶¼º Áֱ⼺ ¸¶ºñ 1¿¹. ´ëÇÑ ³»ºÐºñÇÐȸ. 23(6):425-429, 20081201. 48. È«Àº°æ. ¼ºÀκñ¸¸ÀÇ º´ÀÎ ¹× °ü·ÃÁúȯ. ÀÓ»ó´ç´¢º´ÇÐȸÁö. 9(3):148-152, 2008 49. ÃÖ¼±·É, À̼ºÁø, ÀÌÇظ®, °Áر¸, ·ù¿ÁÇö, ±èö½Ä, À̺´¿Ï, È«Àº°æ, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. °©»ó¼± ¾È±¸º´Áõ°ú µ¿¹ÝµÈ °æ¸· µ¿Á¤¸Æ·ç¿¡ ÀÇÇÑ ÀÏÃø¼º ¾È±¸µ¹Ãâ 1¿¹. ´ëÇѳ»ºÐºñÇÐȸÁö. 23(1):51-55, 2008 50. Wang H, Knaub LA, Jensen DR, Jung DY, Hong EG, Ko HJ, Coates AM, Goldberg IJ, de la Houssaye BA, Janssen RC, McCurdy CE, Rahman SM, Choi CS, Shulman GI, Kim JK, Friedman JE, Eckel RH. Skeletal Muscle-Specific Deletion of Lipoprotein Lipase Enhances Insulin Signaling in Skeletal Muscle but Causes Insulin Resistance in Liver and Other Tissues. Diabetes. 58(1):116-24, 20090101 51. Delibegovic M, Zimmer D, Kauffman C, Rak K, Hong EG, Cho YR, Kim JK, Kahn BB, Neel BG, Bence KK. Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress. Diabetes. 58(3):590-9, 20090301 52. È«Àº°æ. Çѱ¹ÀÎ ¼ºÀÎ ´ç´¢º´È¯ÀÚ¿¡¼ Ç× GAD Ç×ü ¾ç¼º·ü. Korean Diabetes Journal. 33(1): 13-5, 20090201 53. È«Àº°æ. Á¦2Çü ´ç´¢º´°ú ¾Ï ¹ß»ýÀÇ ¿¬°ü¼º. ÀÓ»ó´ç´¢º´. 10(1): 11-15, 20090401 54. ÃÖÁ¾¼ö, ÀÌÇظ®, °Áر¸, ·ù¿ÁÇö, ±èö½Ä, À̺´¿Ï, À̼ºÁø, ±èÇö±Ô, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ, È«Àº°æ. ¿Ü»óÈÄ ÀÌÅëÀ» ÁÖ¼Ò·Î ³»¿øÇÑ Á¦2Çü ´ç´¢º´È¯ÀÚÀÇ ºñ-¾È¿Í-³ú ¹ÂÄÚ¸£Áø±ÕÁõ 1¿¹. ÀÓ»ó´ç´¢º´(Ã¥ÀÓÀúÀÚ). 10(1): 57-61, 20090401 55. ÀÌÇظ®, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ, È«Àº°æ. Çѱ¹ÀÎ Á¦2Çü ´ç´¢º´È¯ÀÚ¿¡¼ Á¶±â ´ëÇ÷°ü ÇÕº´Áõ ¹ß»ý°ú °ü·ÃµÈ À§Çè ÀÎÀÚ. Korean Diabetes Journal(Ã¥ÀÓÀúÀÚ). 33(2): 134-142, 20090501 56. Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, Granger EL, Norbury CC, Hauschka SD, Philbrick WM, Lee CG, Elias JA, Kim JK. Interleukin-10 Prevents Diet-Induced Insulin Resistance by Attenuating Macrophage and Cytokine Response in Skeletal Muscle. Diabetes(Á¦1ÀúÀÚ). 58(11): 2525-35, 20090818 57. Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, Fernandez MR, Fisher K, Kortum RL, Hong EG, Jun JY, Ko HJ, Schreiner A, Volle DJ, Treece T, Swift AL, Winer M, Chen D, Wu M, Leon LR, Shaw AS, McNeish J, Kim JK, Morrison DK. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 10(5):366-78, 20091101 58. Lee JM, Kim JH, Son HS, Hong EG, Yu JM, Han KA, Min KW, Chang SA. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. The Journal of international medical research. 38(1): 234-41, 20100201 59. Yew NS, Zhao H, Hong EG, Wu IH, Przybylska M, Siegel C, Shayman JA, Arbeeny CM, Kim JK, Jiang C, Cheng SH. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One. 5(6): e11239, 20100601 60. Kim CS, Park SY, Yu SH, Kang JG, Ryu OH, Lee SJ, Hong EG, Kim HK, Kim DM, Yoo JM, Ihm SH, Choi MG, Yoo HJ. Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients?. Korean Diabetes J. 34(3): 174-81, 20100601 61. À̼Èñ, ¹Ú¼Ò¿µ, ±è¹Î°, ±èÀºÁö, À¯¼ºÈÆ, °Áر¸, ·ù¿ÁÇö, ±èö½Ä, À̼ºÁø, È«Àº°æ, ±èµÎ¸¸, À¯Àç¸í, ÀÓ¼ºÈñ, ÃÖ¹®±â, À¯ÇüÁØ. Áö¼ÓÇü Àν¶¸°°ú Àν¶¸° ºÐºñÃËÁøÁ¦¸¦ »ç¿ëÇÏ´Â Á¦2Çü ´ç´¢º´È¯ÀÚ¿¡¼ °øº¹ ¹× ½ÄÈÄ C-peptideÀÇ º¯È¿¡ µû¸¥ Ç÷´çÁ¶Àý»óÅÂ. ÀÓ»ó´ç´¢º´. 11(4):324-32, 2010 62. À̹οµ, ¹Ú±ÔÅÂ, °Áر¸, ·ù¿ÁÇö, ±èö½Ä, À̼ºÁø, ±èÇö±Ô, È«Àº°æ, ±èµÎ¸¸, À¯¼ºÈÆ, ÀÓ¼ºÈñ, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ. Duloxetine Åõ¿© ÈÄ¿¡ ¹ß»ýÇÑ ÁßÁõ Àú³ªÆ®·ýÇ÷Áõ 1¿¹. ÀÓ»ó´ç´¢º´. 11(4):333-6, 2010 63. ÀÌÂù¿ì, À¯¸í½Å, À̹οµ, À̹ÌÁø, ÃÖÁ¾¼ö, °Áر¸, ±èö½Ä, À̼ºÁø, È«Àº°æ, ±èµÎ¸¸, À¯¼ºÈÆ, ÀÓ¼ºÈñ, À¯Àç¸í, ÃÖ¹®±â, À¯ÇüÁØ, ·ù¿ÁÇö. Ketosis-prone ´ç´¢º´ 4¿¹¿¡ ´ëÇÑ ÀÓ»óÀû °íÂû. ÀÓ»ó´ç´¢º´. 11(4):342-348, 2010 64. Lee JM, Kim JH, Son HS, Hong EG, Yu JM, Han KA, Min KW, Chang SA: Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. J Int Med Res 38(1): 234-41, 2010 65. Kim CS, Park SY, Yu SH, Kang JG, Ryu OH, Lee SJ, Hong EG, Kim HK, Kim DM, Yoo JM, Ihm SH, Choi MG, Yoo HJ: Is A1C Variability an Independent Predictor for the Progression of Atherosclerosis in Type 2 Diabetic Patients? Korean Diabetes J 34(3): 174-81, 2010 66. È«Àº°æ ¿Ü 23¸í, ³ëÀδ索º´¼Ò¿¬±¸È¸. ³ëÀδ索º´(Àú¼). 2010 67. È«Àº°æ ¿Ü 90¸í, ´ëÇѳ»ºÐºñÇÐȸ. ³»ºÐºñ´ë»çÇÐ(±³°ú¼). 2011 68. Kim JH, Oh SJ, Lee JM, Hong EG, Yu JM, Han KA, Min KW, Son HS, ChangSA. The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension. Diabetes and Metabolism Journal. 35(3):236-42, 201106 69. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, Woo MH, Kim JY, Kim NH, Kim JT, Kim CH, Kim HJ, Jeong IK, Hong EG, Cho JH, Mok JO, Yoon KH. 2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea. Diabetes and Metabolism Journal. 35(5):431-6, 2011 70. Kim JH, Oh SJ, Lee JM, Hong EG, Yu JM, Han KA, Min KW, Son HS, ChangSA: The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension. Diabetes and Metab J 3:236-242, 2011 71. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, Woo MH, Kim JY, Kim NH, Kim JT, Kim CH, Kim HJ, Jeong IK, Hong EG, Cho JH, Mok JO, Yoon KH: 2011 Clinical Practice Guidelines for Type 2 Diabetes in Korea. Diabetes and Metab J 5:431-436, 2011 72. Hong EG: Drug Therapy of Elderly Diabetic Patients. Korean Int Med 6:635-642, 2011 73. È«Àº°æ ¿Ü ¸í, ´ëÇÑ´ç´¢º´ÇÐȸ. ´ç´¢º´ÇÐ(±³°ú¼). 2011 74. Kim CS, Park JR, Yu SH, Kang JG, Ryu OH, Lee SJ, Hong EG, Kim DM, Yoo JM, Ihm SH, Choi MG, Yoo HJ: Impact of Serum Adiponectin Concentration on Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab 27(1):31-38, 2012 75. Han DH, Moh IH, Kim DM, Ihm SH, Choi MG, Yoo HJ, Hong EG: Gestational hyperlipidemia and acute pancreatitis with underlying partial lipoprotein lipase deficiency and apolipoprotein E3/E2 genotype. Korean J Intern Med. 2013 Sep;28(5):609-13. 76. Hong EG, Kim BW, Jung DY, Lee EJ, Yu T, Da Silva WS, Friedline RH, Russell K, Larsen PR, Bianco AC, Kim JK: Cardiac Expression of Human Type 2 Iodothyronine Deiodinase Increases Glucose Metabolism and Protects Against Doxorubicin- Induced Cardiac Dysfunction in Male Mice. Endocrinology 154:3937-3946, 2013 80. Ohn JH, Kwon IH, Park JR, Ryu OH, Lee SJ, Kim DM, Ihm SH, Choi MG, Yoo HJ, Hong EG. Unprotected daily sun exposure is differently associated with central adiposity and beta-cell dysfunction by gender: The Korean national health and nutrition examination survey (KNHANES) V. Environmental Research 13: 253-259, 2014 81. Choi JE, Lee HR, Ohn JH, Moon MK, Park JR, Lee SJ, Choi MG, Yoo HJ, Kim JH, Hong EG. Adult Multisystem Langerhans Cell Histiocytosis Presenting with Central Diabetes Insipidus Successfully Treated with Chemotherapy. Endocrinol Metab 29:1-6, 2014 82. Yeung RO, Zhang Y, Luk A, Yang W, Sobrepena L, Yoon KH, Aravind SR, Sheu W, Nguyen TK, Ozaki R, Deerochanawong C, Tsang CC, Chan WB, Hong EG, Do TQ, Cheung Y, Brown N, Goh SY, Ma RC, Mukhopadhyay M, Ojha AK, Chakraborty S, Kong AP, Lau W, Jia W, Li W, Guo X, Bian R, Weng J, Ji L, Rosa MR, Toledo RM, Himathongkam T, Yoo SJ, Chow CC, Ho LL, Chuang LM, Tutino G, Tong PC, So WY, Wolthers T, Ko G, Lyubomirsky G, Chan J. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014 Dec;2(12):935-43. 83. Cho IJ, Chung HY, Kim SW, Lee JW, Lee TW, Kim HS, Kim SG, Choi HS, Choi SH, Shin CS, Oh KW, Min YK, Koh JM, Rhee Y, Byun DW, Chung YS, Park JH, Chung DJ, Shong M, Hong EG, Lee CB, Baek KH, Kang MI: Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis. Endocrinol Metab (Seoul). 2015 Sep;30(3):272-9. 84. Lee S, Choi MG, Yu J, Ryu OH, Yoo HJ, Ihm SH, Kim DM, Hong EG, Park KT, Choi MJ, Choi HH. The effects of the Korean reference value on the prevalence of osteoporosis and the prediction of fracture risk. BMC Musculoskeletal Disorders 2015 Oct 6;15:114. doi: 10.1186/s12872-015-0109-y. 85. Hong EG, Ohn JH, Lee SJ, Kwon HS, Kim SG, Kim DJ, Kim DS. Clinical implications of carotid artery intima media thickness assessment on cardiovascular risk stratification in hyperlipidemic Korean adults with diabetes: the ALTO study. BMC Cardiovasc Disord. 2015 Oct 6;15:114. doi: 10.1186/s12872-015-0109-y. 86. Luk AO, Li X, Zhang Y, Guo X, Jia W, Li W, Weng J, Yang W, Chan WB, Ozaki R, Tsang CC, Mukhopadhyay M, Ojha AK, Hong EG, Yoon KH, Sobrepena L, Toledo RM, Duran M, Sheu W, Q Do T, Nguyen TK, Ma RC, Kong AP, Chow CC, Tong PC, So WY, Chan JC; JADE Study Group. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. Diabet Med. 2016 Sep;33(9):1230-9. 87. Choi YM, Kim WG, Kwon H, Jeon MJ, Lee JJ, Ryu JS, Hong EG, Kim TY, Shong YK, Kim WB. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma.: Eur J Endocrinol. 2016 Sep;175(3):165-72. 88. Goh SY, Ang E, Bajpai S, Deerochanawong C, Hong EG, Hussein Z, Joshi S, Kamaruddin NA, Kho S, Kong AP, Pan CY, Perfetti R, Vichayanrat A, Vlajnic A, Chan JC. A patient-centric approach to optimise insulin therapy in Asia.: J Diabetes Complications. 2016 Aug;30(6):973-80. 89. Cho A, Noh JW, Kim JK, Yoon JW, Koo JR, Lee HR, Hong EG, Lee YK. Prevalence and Prognosis of hypoglycemia in Patients Receiving Maintenance Dialysis. Intern Med J. 2016 Dec;46(12):1380-1385 90. Choi YM, Kim WG, Kwon H, Jeon MJ, Han M, Kim TY, Shong YK, Hong SM, Hong EG, Kim WB. Changes in standardized mortality rates from thyroid cancer in Korea between 1985 and 2015: Analysis of Korean national data. Cancer. 2017 Dec 15;123(24):4808-4814. 100. Hong SM, Choi YM, Ihm SH, Kim D, Choi MG, Yu JM, Hong EG. Association between metabolic parameters and glomerular hyperfiltration in a representative Korean population without chronic kidney disease. PLoS One. 2018 Dec 6;13(12):e0207843. 101. Bae JC, Min KW, Kim YH, Kim KA, Hong EG, Park CY, Han S, Cha BS. Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial. Diabetes Obes Metab. 2019 Jan;21(1):103-111 102. Hong EG. Changes in Glucose Metabolism with Aging. J Korean Diabetes 2019;20:215-219. 103. Choi YM, Kwak MK, Hong SM, Hong EG. Changes in thyroid peroxidase and thyroglobulin antibodies might be associated with Graves¡¯ disease relapse after antithyroid drug therapy. Endocrinol Metab 2019;34:268-274. 104. Choi YM, Kwon HS, Choi KM, Lee WY, Hong EG. Short-Term Effects of Beraprost Sodium on the Markers for Cardiovascular Risk Prediction in Type 2 Diabetic Patients with Microalbuminuria. Endocrinol Metab 2019;34:398-405. 105. Ko MS, Yun JY, Baek IJ, Jang JE, Hwang JJ, Lee SE, Heo SH, Bader DA, Lee CH, Han J, Moon JS, Lee JM, Hong EG, Lee IK, Kim SW, Park JY, Hartig SM, Kang UJ, Moore DD, Koh EH, Lee KU. Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice. Autophagy. 2020 May 13:1-17. 106. Choi YM, Lim J, Jeon MJ, Lee YM, Sung TY, Hong EG, Lee JY, Jang SJ, Kim WG, Song DE, Chun SM. Mutation Profile of Aggressive Pheochromocytoma and Paraganglioma with Comparison of TCGA Data. Cancers (Basel). 2021 May 14;13(10):2389. doi: 10.3390/cancers13102389 107. Choi YM, Kim MK, Kwak MK, Kim D, Hong EG. Association between thyroid hormones and insulin resistance indices based on the Korean National Health and Nutrition Examination Survey. Sci Rep. 2021 Nov 5;11(1):21738. doi: 10.1038/s41598-021-01101-z. 108. Chan JCN, Thewjitcharoen Y, Nguyen TK, Tan A, Chia YC, Hwu CM, Jian D, Himathongkam T, Wong KL, Choi YM, Mirasol R, Mohamed M, Kong APS, Ma RCW, Chow EYK, Ozaki R, Lau V, Fu AWC, Hong EG, Yoon KH, Tsang CC, Lau ESH, Lim LL, Luk AOY. Effect of a Web-Based Management Guide on Risk Factors in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A JADE Randomized Clinical Trial. JAMA Netw Open. 2022 Mar 1;5(3):e223862. doi: 10.1001/jamanetworkopen.2022.3862. 109. Choi YM, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, Kim WB, Kim WG. Recent Changes in the Incidence of Thyroid Cancer in Korea between 2005 and 2018: Analysis of Korean National Data. Endocrinol Metab (Seoul). 2022 Oct;37(5):791-799. doi: 10.3803/EnM.2022.1533. Epub 2022 Oct 11. 110. Kwak MK, Ha ES, Lee J, Choi YM, Kim BJ, Hong EG. C-C motif chemokine ligand 2 promotes myogenesis of myoblasts via the AKT-mTOR pathway. Aging (Albany NY). 2022 Dec 27;14(24): 9860-9876. doi: 10.18632/aging.204451. Epub 2022 Dec 27. 111. Lee BW, Min K, Hong EG, Ku BJ, Kang JG, Chon S, Lee WY, Park MK, Kim JH, Kim SY, Song K, Yoo SJ. Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION). Endocrinol Metab (Seoul). 2023 Jun;38(3):328-337. doi: 10.3803/EnM.2023.1688. Epub 2023 Jun 28. 112. Yang YS, Min KW, Park SO, Kim KS, Yu JM, Hong EG, Cho SR, Won KC, Kim YH, Oh S, Choi SH, Koh G, Huh W, Kim SY, Park KS. Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12-week, multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Obes Metab. 2023 Aug;25(8):2096-2104. doi: 10.1111/ dom.15080. Epub 2023 Apr 24. 113. Han KA, Kim YH, Kim DM, Lee BW, Chon S, Sohn TS, Jeong IK, Hong EG, Son JW, Nah JJ, Song HR, Cho SI, Cho SA, Yoon KH. Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial. Diabetes Metab J. 2023 Feb 9. doi: 10.4093/dmj.2022.0315. Online ahead of print 114. Choi YM, Kim MJ, Lee J, Kwak MK, Jeon MJ, Kim TY, Hong EG, Kim WB, Kim WG. Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020. Endocrinol Metab (Seoul). 2023 Oct;38(5):588-595. doi: 10.3803/EnM.2023.1723. Epub 2023 Sep 8 115. Moon JS, Park IR, Kim HJ, Chung CH, Won KC, Han KA, Park CY, Won JC, Kim DJ, Koh GP, Kim ES, Yu JM, Hong EG, Lee CB, Yoon KH. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension. Diabetes Metab J. 2023 47(6):808-817. 116. Choi KY, Kim TY, Chon YE, Kim MN, Lee JH, Hwang SG, Lee J, Kwak MK, Hong EG, Choi YM, Ha Y. Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2023 14(6):2747-2756. 117. Heo JH, Han KA, Hong JH, Seo HA, Hong EG, Yu JM, Jung HS, Cha BS. Pioglitazone as Add-on THERAPY in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial. Diabetes Metab J. 2024 Feb 2. doi: 10.4093/dmj.2023.0314. Online ahead of print. 118. Sohn TS, Han KA, Kim Y, Lee BW, Chon S, Jeong IK, Hong EG, Son JW, Na J, Cho JM, In Cho S, Huh W, Yoon KH. A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study. Diabetes Obes Metab. 2024 26(6):2248-2256. 119. Hong EG, Min KW, Lim JS, Ahn KJ, Ahn CW, Yu JM, Kim HS, Kim HJ, Kim W, Kim DH, Jang HC. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study. Adv Ther. 2024 41(5):1967-1982. 120. Kim NH, Lee J, Chon S, Yu JM, Jeong IK, Lim S, Kim WJ, Song K, Cho HC, Yu HM, Kim KA, Kim SS, Lee SH, Kim CH, Kwak SH, Lee YH, Chung CH, Lee S, Jin HY, Lee JH, Koh G, Kim SY, Kim J, Lee JH, Kim TN, Jeon HJ, Lee JH, Jeon JH, Yoo HJ, Kim HK, Park HK, Nam-Goong IS, Hong S, Ahn CW, Yu JH, Park JH, Park KG, Park CH, Joung KH, Ryu OH, Park KY, Hong EG, Cha BS, Won KC, Chung YS, Kim SG. Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE). Endocrinol Metab (Seoul). 2024 Aug 22. doi: 10.3803/EnM.2024.1995. Online ahead of print. Àú¼/Àú¼ú Àú¼(°øÀú) 1. ³ëÀδ索º´ ´ëÇÑ´ç´¢º´ÇÐȸ ³ëÀδ索º´ ¼Ò¿¬±¸È¸ pp205-214, 2003, 2018 2. ¼ºÀκ´ºñ¹ý¼ ±ºÀÚÃâÆÇ»ç Á¦1ÆÇ pp167-180, 2007 3. ¼ºÀÎ ¼ºÀåÈ£¸£¸ó Ä¡·á ¼ºÀÎÆí. ´ëÇѳ»ºÐºñÇÐȸ ¼ºÀμºÀåÈ£¸£¸ó ¿¬±¸È¸ pp184-198, 2005 4. ¸»´Üºñ´ëÁõ Áø·áÁöħ(³»ºÐºñÇÐȸ, ÁÖÀúÀÚ) 5. ´ç´¢º´ÇÐ(´ëÇÑ´ç´¢º´ÇÐȸ) 6. ³»ºÐºñ´ë»çÇÐ(´ëÇѳ»ºÐºñÇÐȸ) 7. Çظ®½¼ ³»°úÇÐ(¹ø¿ª¼) 8. ´ë»çÁõÈıº |